Acacia Pharma Group plc Acacia Pharma Group Plc - Total Number Of Voting Rights And Capital
01 April 2022 - 3:00AM
UK Regulatory
TIDMACPH
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
Publication in application of Article 15 of the Law of 2 May 2007
(the Transparency Law)
-----------------------------------------------------------------
Cambridge, UK and Indianapolis, US -- 31 March 2022, 18:00 CET.
As previously announced(1) , Acacia Pharma Group plc issued
ordinary shares to its Employee Benefit Trust within the authorised
capital. The gross amount of this capital increase amounted to GBP
1,274,20 via an issue of 63,710 new shares at an issue price of GBP
0.02 per share. The shares were issued to satisfy the vesting of
share awards granted under the Company's Performance Share
Plan.
Total amount of share capital on 31
March 2022 GBP 2,018,462.66
------------------------------------- ------------------
Total amount of share premium on 31
March 2022 GBP 141,239,460.66
------------------------------------- ------------------
Total number of shares with voting
rights on 31 March 2022 100,923,133
------------------------------------- ------------------
Total number of voting rights on 31
March 2022 (denominator) 100,923,133
------------------------------------- ------------------
Total number of outstanding warrants 201,330
------------------------------------- ------------------
Total number of outstanding employee
share options and RSUs(2) 5,939,424
------------------------------------- ------------------
1. Press release of 15 March 2022 -- Issue of Shares to Employee Benefit
Trust
2. Of the 5,939,424 options and RSUs currently outstanding, 1,002,584 will
be satisfied through the transfer of shares already issued and admitted
to trading and held within the Acacia Pharma Group plc Employee Benefit
Trust
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Frazer Hall, Mark Swallow, David
+44 1223 919760 / +1 317 505 1280 Dible
IR@acaciapharma.com MEDiSTRAVA Consulting
+44 20 3928 6900
acaciapharma@citigatedewerogerson.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH,
United Kingdom
Company number 9759376
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride
injection) is marketed in the US for the management of
postoperative nausea & vomiting (PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid
onset/offset IV benzodiazepine sedative is approved and launched in
the US for use during invasive medical procedures in adults lasting
30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is
in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centered in Cambridge, UK. The Company
is listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
www.acaciapharma.com
(END) Dow Jones Newswires
March 31, 2022 12:00 ET (16:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024
